Canopy Growth Corp Transfers 1,500 Cannabis Clones to Spain for Madrid Based Operations | CashCropToday
0 Shares 196 Views

Canopy Growth Corp Transfers 1,500 Cannabis Clones to Spain for Madrid Based Operations

March 19, 2018
196 Views

Canopy Growth Corporation (TSX: WEED) has announced this morning that the company has completed the first phase of their partnership with Spanish company Alcaliber SA. Canopy has successfully transferred 1,500 cannabis clones to Spain for cultivation.

Canopy has transferred the 1,500 cannabis clones to Alcaliber’s Spanish cultivation facility. Under the terms of the agreement, Canopy will sell its Tweed branded products around Europe, while Alcaliber will focus on producing a variety of cannabis genetics to supply the company.  The partnership was entered into back in September 2o17.

Alcaliber SA is one of the leading pharmaceutical companies in Europe and produces 27% of the worlds morphine supply.

Canopy Growth Corporation continues its dominance of the Canadian public cannabis sector. This news marks the third continent that  will plant its clones on.

 

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
272 views
Market Watch
272 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
195 views
Global
195 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
191 views
Manufacturing
191 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: